Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, An Anti-Glypican3 (GPC3)/CD3 Bispecific Antibody, in Patients With Advanced Solid Tumors

NCT02748837 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT02748837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02748837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, An Anti-Glypican3 (GPC3)/CD3 Bispecific Antibody, in Patients With Advanced Solid Tumors
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2016
Completion date
August 31, 2019
Enrollment
29 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors